Cytokinetics, Incorporated (ETR:KK3A)
| Market Cap | 6.44B -6.2% |
| Revenue (ttm) | 99.76M +29.9% |
| Net Income | -685.01M |
| EPS | -5.49 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 46.36 |
| Previous Close | 46.82 |
| Day's Range | 46.36 - 47.30 |
| 52-Week Range | 46.77 - 77.30 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Cytokinetics
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in h... [Read more]
Financial Performance
In 2025, Cytokinetics's revenue was $88.04 million, an increase of 376.56% compared to the previous year's $18.47 million. Losses were -$784.96 million, 33.2% more than in 2024.
Financial numbers in USD Financial StatementsNews
Cytokinetics price target lowered to $100 from $103 at JPMorgan
JPMorgan lowered the firmâs price target on Cytokinetics (CYTK) to $100 from $103 and keeps an Overweight rating on the shares. The firm updated the companyâs model post the Q3âŠ
Cytokinetics Transcript: Jefferies Global Healthcare Conference
MYQORZO's launch is exceeding expectations, while MAPLE-HCM supports earlier treatment consideration. A 2027 nHCM expansion could double the addressable market, with slower titration and real-world evidence shaping use and REMS discussions.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 13, 2026 it granted stock options to purchase an aggregate of ...
Cytokinetics Transcript: UBS Global Biopharma Conference 2026
MYQORZO is gaining U.S. prescribing share, with MAPLE data added to its label and more than 80% of symptomatic, diagnosed oHCM patients still outside CMI therapy. Global launches, potential nHCM expansion and real-world evidence to support REMS changes are key growth priorities.
Cytokinetics announces FDA approval for Myqorzo sNDA
Cytokinetics (CYTK) announced that the FDA has approved a supplemental new drug application, or sNDA, updating the U.S. Prescribing Information for Myqorzo to include data from MAPLE-HCM, the Phase 3âŠ
Cytokinetics Announces Prescribing Information for MYQORZOÂź (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM
MYQORZO is the Only Cardiac Myosin Inhibitor with Data in Its U.S. Label Comparing Its Effectiveness to the Beta Blocker Metoprolol
Cytokinetics Transcript: Stifel 2026 Healthcare Conference 2026
Revenue rose 76% QoQ and dispenses exceeded 2,800; new-to-brand share approached 45% after eight months. Upcoming priorities include the nHCM submission by year-end and potential European activity in early 2027.
Cytokinetics announces additional aficamten data in hypertrophic cardiomyopathy
Cytokinetics (CYTK) announced that new data related to aficamten were presented at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions held in collaboration with the American Heart Ass...
Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026
New Analyses Across Obstructive and Non-obstructive HCM Expand Clinical Evidence for Aficamten
Cytokinetics price target raised to $105 from $99 at Citi
Citi raised the firmâs price target on Cytokinetics (CYTK) to $105 from $99 and keeps a Buy rating on the shares post the Q3 report. The firm says Myqorzo showedâŠ
Cytokinetics Earnings Call Transcript: Q3 2026
MYQORZO revenue reached $44.5M, up 76% QoQ, with expanding U.S. prescribing and European launches. Aficamtenâs nHCM sNDA is on track for Q4 2026 as pipeline programs advance.
Cytokinetics Earnings release: Q3 2026
Cytokinetics released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Cytokinetics Quarterly report: Q3 2026
Cytokinetics has published its Q3 2026 quarterly earnings report on November 4, 2026.
Cytokinetics reports Q3 EPS ($1.37), consensus ($1.41)
Reports Q3 revenue $47.56M, consensus $42.34M. âOur third quarter results demonstrate continued strong execution as Cytokinetics (CYTK) enters its next phase of growth as a global specialty cardiology...
Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update
MYQORZO Âź (aficamten) Net Product Revenue of $44.5 Million Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 and Type II Variation in the European Union in Early 2027 ~...
Cytokinetics to Participate in November Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following i...
Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming presentations, including two Late Breaking Oral Abstract present...
Cytokinetics to Announce Third Quarter Results on November 4, 2026
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2026 at 4:0...
Cytokinetics price target lowered to $81 from $85 at BofA
BofA lowered the firmâs price target on Cytokinetics (CYTK) to $81 from $85 and keeps a Neutral rating on the shares. The firm updated estimates ahead of Q3 earnings reportsâŠ
Cytokinetics announces Health Canada approval of Myqorzo for oHCM treatment
Cytokinetics (CYTK) announced that Health Canada has issued a Notice of Compliance authorizing Myqorzo for the treatment of symptomatic obstructive hypertrophic cardiomyopathy, or oHCM, of New York He...
Cytokinetics Announces Health Canada Approval of MYQORZOÂź (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Health Canada has issued a Notice of Compliance authorizing MYQORZOÂź (afic...
Cytokinetics initiated with an Outperform at William Blair
William Blair analyst Alethia Young initiated coverage of Cytokinetics (CYTK) with an Outperform rating. Cytokinetics is a commercial-stage specialty cardiology company built around muscle biology and...
Cytokinetics price target lowered to $104 from $115 at UBS
UBS lowered the firmâs price target on Cytokinetics (CYTK) to $104 from $115 and keeps a Buy rating on the shares. Cytokinetics offers an attractive oHCM launch opportunity with nHCMâŠ
Cytokinetics announces additional data from ACACIA-HCM trial at HFSA
Cytokinetics (CYTK) announced that additional data from ACACIA-HCM were presented at the Heart Failure Society of America, or HFSA, annual scientific meeting in Phoenix, Arizona. Data from a prespecif...
Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCM